当前位置: X-MOL 学术J. Pineal. Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice.
Journal of Pineal Research ( IF 8.3 ) Pub Date : 2019-12-06 , DOI: 10.1111/jpi.12623
Jae-Hyung Park 1 , Incheol Seo 1 , Hae-Min Shim 1 , Hochan Cho 2
Affiliation  

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are effective hypoglycemic agents that can induce glycosuria. However, there are increasing concerns that they might induce diabetic ketoacidosis. This study investigated the effect of melatonin on SGTL2i-induced ketoacidosis in insulin-deficient type 2 diabetic (T2D) mice. The SGLT2i dapagliflozin reduced blood glucose level and plasma insulin concentrations in T2D mice, but induced increases in the concentrations of plasma β-hydroxybutyrate, acetoacetate, and free fatty acid and a decrease in the concentration of plasma bicarbonate, resulting in ketoacidosis. Melatonin inhibited dapagliflozin-induced ketoacidosis without inducing any change in blood glucose level or plasma insulin concentration. In white adipose tissue, melatonin inhibited lipolysis and downregulated phosphorylation of PKA, HSL, and perilipin-1. In liver tissue, melatonin suppressed cellular cyclic AMP levels and downregulated phosphorylation of PKA, AMPK, and acetyl-CoA carboxylase (ACC). In addition, melatonin increased hepatic ACC activity, but decreased hepatic CPT1a activity and acetyl-CoA content. These effects of melatonin on lipolysis and hepatic ketogenesis were blocked by pretreatment with melatonin receptor antagonist or PKA activator. Collectively, these results suggest that melatonin can ameliorate SGLT2i-induced ketoacidosis by inhibiting lipolysis and hepatic ketogenesis though cyclic AMP/PKA signaling pathways in T2D mice. Thus, melatonin treatment may offer protection against SGLT2i-induced ketoacidosis.

中文翻译:

褪黑素通过抑制2型糖尿病小鼠的脂解作用和肝生酮作用来改善SGLT2抑制剂诱导的糖尿病酮症酸中毒。

钠葡萄糖共转运蛋白2抑制剂(SGLT2i)是有效的降糖药,可诱导糖尿症。但是,人们越来越担心它们可能诱发糖尿病性酮症酸中毒。这项研究调查了褪黑素对胰岛素缺乏型2型糖尿病(T2D)小鼠中SGTL2i诱导的酮症酸中毒的影响。SGLT2i dapagliflozin降低了T2D小鼠的血糖水平和血浆胰岛素浓度,但诱导血浆β-羟基丁酸酯,乙酰乙酸盐和游离脂肪酸的浓度增加以及血浆碳酸氢盐的浓度降低,从而导致酮症酸中毒。褪黑素抑制达格列净诱导的酮症酸中毒,而不会引起血糖水平或血浆胰岛素浓度的任何变化。在白色脂肪组织中,褪黑素抑制脂解作用,并下调PKA,HSL,和periplin-1。在肝脏组织中,褪黑素抑制细胞周期AMP水平,并下调PKA,AMPK和乙酰辅酶A羧化酶(ACC)的磷酸化。此外,褪黑素增加了肝ACC活性,但降低了肝CPT1a活性和乙酰辅酶A含量。褪黑激素对脂质分解和肝酮生成的这些作用被褪黑激素受体拮抗剂或PKA活化剂预处理所阻断。总体而言,这些结果表明褪黑素可以通过脂类和肝酮生成的抑制,通过循环AMP / PKA信号通路在T2D小鼠中减轻SGLT2i诱导的酮症酸中毒。因此,褪黑激素治疗可提供针对SGLT2i诱导的酮症酸中毒的保护作用。和乙酰辅酶A羧化酶(ACC)。此外,褪黑素增加了肝ACC活性,但降低了肝CPT1a活性和乙酰辅酶A含量。褪黑激素对脂质分解和肝酮生成的这些作用被褪黑激素受体拮抗剂或PKA活化剂预处理所阻断。总体而言,这些结果表明褪黑素可以通过脂类和肝酮生成的抑制,通过循环AMP / PKA信号通路在T2D小鼠中减轻SGLT2i诱导的酮症酸中毒。因此,褪黑激素治疗可提供针对SGLT2i诱导的酮症酸中毒的保护作用。和乙酰辅酶A羧化酶(ACC)。此外,褪黑素增加了肝ACC活性,但降低了肝CPT1a活性和乙酰辅酶A含量。褪黑激素对脂质分解和肝酮生成的这些作用被褪黑激素受体拮抗剂或PKA活化剂预处理所阻断。总体而言,这些结果表明褪黑素可以通过脂类和肝酮生成的抑制,通过循环AMP / PKA信号通路在T2D小鼠中减轻SGLT2i诱导的酮症酸中毒。因此,褪黑激素治疗可提供针对SGLT2i诱导的酮症酸中毒的保护作用。总体而言,这些结果表明褪黑素可以通过脂类和肝酮生成的抑制,通过循环AMP / PKA信号通路在T2D小鼠中减轻SGLT2i诱导的酮症酸中毒。因此,褪黑激素治疗可提供针对SGLT2i诱导的酮症酸中毒的保护作用。总体而言,这些结果表明褪黑素可以通过脂类和肝酮生成的抑制,通过循环AMP / PKA信号通路在T2D小鼠中减轻SGLT2i诱导的酮症酸中毒。因此,褪黑激素治疗可提供针对SGLT2i诱导的酮症酸中毒的保护作用。
更新日期:2019-12-06
down
wechat
bug